Endocrinology 2015-04-01

Baseline anandamide levels and body weight impact the weight loss effect of CB1 receptor antagonism in male rats.

Cecilia Karlsson, Stephan Hjorth, Martin Karpefors, Göran I Hansson, Björn Carlsson

Index: Endocrinology 156(4) , 1237-41, (2015)

Full Text: HTML

Abstract

The individual weight loss response to obesity treatment is diverse. Here we test the hypothesis that the weight loss response to the CB1 receptor antagonist rimonabant is influenced by endogenous levels of receptor agonists. We show that baseline anandamide levels and body weight independently contribute to predict the treatment response to rimonabant in rodents, demonstrating that addition of biomarkers related to mode of action is relevant for a personalized health care approach to obesity treatment.